Seth D. Lewis
Investor Relations Contact chez MOLECULAR PARTNERS AG
Profil
Seth D.
Lewis is currently working as the SVP-Investor Relations, Communications & Strategy at Molecular Partners AG since 2019.
Previously, he held positions as the VP-Investor Relations & Communications at Bavarian Nordic, Inc., Vice President at Trout Capital LLC, Financial Consultant at Smith Barney & Co., Inc., Senior Vice President at The Trout Group LLC, and Vice President-Investor Relations & Communications at Surface Oncology, Inc. Mr. Lewis completed his undergraduate degree at Hartwick College.
Postes actifs de Seth D. Lewis
| Sociétés | Poste | Début |
|---|---|---|
| MOLECULAR PARTNERS AG | Investor Relations Contact | 01/11/2019 |
Anciens postes connus de Seth D. Lewis
| Sociétés | Poste | Fin |
|---|---|---|
The Trout Group LLC
 The Trout Group LLC Financial ConglomeratesFinance The Trout Group LLC operates as an investor relations and strategic advisory firm servicing the life science industry. It offers investor relations strategy, targeting and outreach, market intelligence, investor relation event planning and execution, investor relations materials, and corporate communications services. The company was founded by Jonathan B. Fassberg in 2004 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
Bavarian Nordic, Inc.
 Bavarian Nordic, Inc. Miscellaneous Commercial ServicesCommercial Services Bavarian Nordic, Inc. engages in researching and manufacturing drugs to treat cancer. The company is headquartered in Morrisville, NC. | Investor Relations Contact | - |
| Smith Barney & Co., Inc. | Corporate Officer/Principal | - |
| SURFACE ONCOLOGY, INC. | Investor Relations Contact | - |
Trout Capital LLC
 Trout Capital LLC Investment Banks/BrokersFinance The Trout Group LLC is an investor relations and strategic advisory firm exclusively serving the life sciences industry. Since 1995, they have been providing companies in the sector with access to the U.S. institutional investment community. Trout is headquartered in New York and has additional offices in Waltham, Massachusetts and San Francisco. | Corporate Officer/Principal | - |
Formation de Seth D. Lewis
| Hartwick College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| MOLECULAR PARTNERS AG | Health Technology |
| Entreprise privées | 5 |
|---|---|
Bavarian Nordic, Inc.
Bavarian Nordic, Inc. Miscellaneous Commercial ServicesCommercial Services Bavarian Nordic, Inc. engages in researching and manufacturing drugs to treat cancer. The company is headquartered in Morrisville, NC. | Commercial Services |
Trout Capital LLC
Trout Capital LLC Investment Banks/BrokersFinance The Trout Group LLC is an investor relations and strategic advisory firm exclusively serving the life sciences industry. Since 1995, they have been providing companies in the sector with access to the U.S. institutional investment community. Trout is headquartered in New York and has additional offices in Waltham, Massachusetts and San Francisco. | Finance |
| Smith Barney & Co., Inc. | Finance |
The Trout Group LLC
The Trout Group LLC Financial ConglomeratesFinance The Trout Group LLC operates as an investor relations and strategic advisory firm servicing the life science industry. It offers investor relations strategy, targeting and outreach, market intelligence, investor relation event planning and execution, investor relations materials, and corporate communications services. The company was founded by Jonathan B. Fassberg in 2004 and is headquartered in New York, NY. | Finance |
Surface Oncology, Inc.
 Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |
